Cross-sectional Characterization of Idiopathic Bronchiectasis
Cross-Sectional Characterization of Idiopathic Bronchiectasis
2 other identifiers
observational
275
2 countries
6
Brief Summary
Background: \- Bronchiectasis is a type of lung condition in which the lungs airways are abnormally stretched and widened. This stretching and widening makes it difficult for mucus and other substances to move out of the lungs, encouraging the growth of bacteria and leading to breathing problems or infection. Bronchiectasis can be caused by genetic disorders or diseases such as tuberculosis or rheumatoid arthritis. Researchers are interested in developing better ways to diagnose and treat a lung problem called idiopathic or unexplained bronchiectasis. Objectives: \- To better describe the physical characteristics, radiographic patterns, and airway microbiology of unexplained bronchiectasis and to look for possible genetic links or risk factors. Eligibility:
- Individuals at least 18 years of age who have a chronic cough and who have had a CT scan that has revealed signs of bronchiectasis.
- Current smokers or those who have smoked for at least 10 years, as well as individuals who have known causes of bronchiectasis or who have had organ transplants, are not eligible to participate. Design:
- Participants will have one outpatient clinic visit for evaluation with a physical examination including detailed body size measurements and medical history and for collection of blood samples for routine lab tests and genetic analyses and a chest x-ray if no recent one is available.
- Participants will also have tests of lung function, and measurement of a gas called nitric oxide in the nose. Participants whose initial tests show abnormal results may also be asked to have a nasal scrape to collect cell samples and/or a skin sweat test to measure salt concentrations.
- Participants will also have a sputum specimen collected during the visit and will be asked to collect two additional early morning sputum samples and a mouth rinse at home within 2 weeks of the clinic visit, and mail the sample collection materials to the research team.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
6 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 18, 2010
CompletedFirst Posted
Study publicly available on registry
December 21, 2010
CompletedStudy Start
First participant enrolled
April 26, 2011
CompletedJanuary 5, 2026
July 8, 2025
December 18, 2010
January 1, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Clinical characteristics by gender and NTM
Clinical characteristics by gender and NTM status including body morphotypes, radiographic patterns, and respiratory flora
30 years
Secondary Outcomes (1)
Seek to define Genotype/phenotype
30 years
Study Arms (1)
1
Adults with idiopathic bronchiectasis
Eligibility Criteria
Adults with idiopathic bronchiectasis, with stratification by gender and by presence/absence of respiratory infection with nontuberculous mycobacteria (NTM)
You may qualify if:
- The criteria for participants to enter the study mandates that each patient have received a standard (current clinical practice) diagnostic evaluation that includes a CT scan of the chest to document bronchiectasis, prior to enrolling in the Consortium study. To enter this protocol, adults must have bronchiectasis and meet the following criteria:
- Males or females, age greater than or equal to18 years
- Chronic cough
- An available CT of the chest (on a CD) that shows evidence of dilated airways fulfilling radiographic criteria for bronchiectasis in more than one lobe
- Ability to provide informed consent, including HIPAA consent
You may not qualify if:
- A participant should not be in the study if they have not had a standard clinical evaluation to rule out other potential causes of chronic sino-pulmonary disease.
- Known diagnosis of cystic fibrosis with classic clinical presentation and elevated sweat chloride levels and/or two known disease-causing CFTR mutations
- History of tuberculosis or other known explanation for bronchiectasis, such as alpha 1-antitrypsin deficiency (ZZ or ZS), confirmed or probable PCD, inflammatory bowel disease, rheumatoid arthritis, Sjogren s syndrome, allergic bronchopulmonary aspergillosis, or documented primary or acquired immunodeficiency
- Current smoker or \> 10 pack-year history of tobacco use
- Prior solid organ transplant
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (6)
Stanford Medical Center
Stanford, California, 94305, United States
National Jewish Health
Denver, Colorado, 80206, United States
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Washington University, St. Louis
St Louis, Missouri, 63110, United States
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27514, United States
St. Michael's Hospital
Toronto, Canada
Related Publications (1)
Wanner A, Salathe M, O'Riordan TG. Mucociliary clearance in the airways. Am J Respir Crit Care Med. 1996 Dec;154(6 Pt 1):1868-902. doi: 10.1164/ajrccm.154.6.8970383. No abstract available.
PMID: 8970383BACKGROUND
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Andrew J Lipton, M.D.
National Heart, Lung, and Blood Institute (NHLBI)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- NIH
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 18, 2010
First Posted
December 21, 2010
Study Start
April 26, 2011
Last Updated
January 5, 2026
Record last verified: 2025-07-08